Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Otsuka Pharmaceutical Development & Commercialization, Inc.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with DSM-IV diagnosis of schizophrenia patients in acute relapse
Treated as outpatients for at least one continuous 3-month period during the past 12 months
PANSS total score ≥60
Previously responsive to neuroleptics (other than clozapine)
Able to give informed consent and comprehend and satisfactorily comply with the protocol requirements
You may not be if
An Axis I (DSM-IV) diagnosis of schizoaffective disorder
A clinical picture and/or history that was consistent with: (a) Delirium, dementia, amnestic or other cognitive disorders; (b) Bipolar disorder; (c)personality disorder
Nonresponsive to prior olanzapine therapy
Likely to require prohibited concomitant therapy
DSM-IV criteria for any significant substance abuse within the past three months, including addiction to cocaine or alcohol
Known to be allergic or hypersensitive to study drugs
Represented a significant risk of committing suicide based on history or mental status exam
Unstable thyroid pathology and treatment within the past six months
A history or evidence of a medical condition that would expose the patient to an undue risk
Clinically significant abnormal laboratory test results (including urine drug screen), vital sign, or ECG findings
Clareo Health | Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia
